As a complement for the material regarding the “ Investigating gender differences for effectiveness and side effects of varenicline during smoking cessation treatment ” , with DOI number: http://dx.doi.org/10.1590/1806-9282.66.2.146 published in Journal of the Brazilian Medical Association, 2020;66(02), page 146, we are sending you the Disclosures and Acknowledgments below to be included.
Disclosures and Acknowledgments
Financial Support: Pfizer provided medication (varenicline) and financial support for equipment (computer and CO monitor).
Contributors Statement: VC designed the study, edited and critically reviewed the manuscript, and approved the final version of the manuscript. PDG designed the study, edited and critically reviewed the manuscript, and approved the final version of the manuscript. JMCM designed the study, edited and critically reviewed the manuscript, and approved the final version of the manuscript. AM designed the study, edited and critically reviewed the manuscript, and approved the final version of the manuscript.
Conflict of Interest Statement: Dr. Castaldelli-Maia is a grantee of Pfizer Independent Grant for Learning and Change (IGLC) managed by Global Bridges (Healthcare Alliance for Tobacco Dependence Treatment), hosted by the Mayo Clinic, to support free smoking cessation treatment training in addiction/mental health care units in Brazil (grant IGLC 13513957, PI: Castaldelli-Maia) and Portugal (grant IGLC 25629313, PI: Castaldelli-Maia), which have no relationship with the present study. All other authors have no conflict of interest.
Acknowledgment: None
Publication Dates
-
Publication in this collection
03 July 2020 -
Date of issue
May 2020
